We reviewed the pathophysiology of our previously reported female patient who had
glucocorticoid-responsive
hyperaldosteronism and was treated successfully with daily dose of
dexamethasone (Dex) for 21 years. In this present study, the possibility that the patient may have
17 alpha-hydroxylase deficiency (17-OH-D) mainly in the adrenal could not be ruled out. We therefore reviewed 31 Japanese patients diagnosed as having 17-OH-D with suppressed plasma
renin activity reported in Japan. Among these patients, 9 were found to have a high plasma
aldosterone (Ald) concentration (PAC) (group I). Twenty-one patients had either normal or low-normal PAC and the remaining patient had low urine Ald (group II). The slight cross-reactivity of the anti-Ald-
antibodies used with 17-deoxy-steroids such as
progesterone, 11-deoxycorticosterone and
corticosterone which were increased in both groups did not explain the increased PAC in group I. In the patients in group I and group II with high-normal basal PAC, PAC further increased after
ACTH and was suppressed by Dex. PAC in 2 group I patients, however, did not respond to
angiotensin-II or
angiotensin-III infusion. PAC in patients in group II with low or low-normal basal PAC responded equivocally to
ACTH and Dex. The basal plasma
cortisol in group I was lower than in group II, and plasma
cortisol level after
ACTH in group I appeared to remain at a lower level than that in group II patients. Among the study subjects, 28 showed a negative correlation between basal PAC and plasma
cortisol. A possible discrepancy in the deficiency of
17 alpha-hydroxylase activity in adrenal and gonadal glands was also suggested in three 17-OH-D patients. The pathophysiology of Ald secretion and discrepancy in the deficiency of the
enzyme activities in both glands in 17-OH-D patients was discussed.